NASDAQ · PTCT
PTC Therapeutics, Inc.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
Loading market information…
NASDAQ · SLDB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Solid Biosciences Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Solid Biosciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 6, 2025 |
| -$0.89-12.66% vs estimate |
| $0.00 |
| Q3 2024 | Nov 6, 2024 | -$0.79-17.91% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
23 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $19.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$38.91-$1.58 (-3.9%)
Edgewise Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.79% below the high.
$17.04+$0.06 (+0.35%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
$19.23-$0.09 (-0.47%)
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
